Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant
Conditions: Hepatocellular Carcinoma Recurrent; Hepatocellular Carcinoma Interventions: Drug: Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use Sponsors: Asan Medical Center; Korea Health Industry Development Institute Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
TACE Combined With Donafenib and Tislelizumab in Unresectable Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Interventions: Drug: Transarterial chemoembolization combined with Donafenib and Tislelizumab Sponsors: Guangxi Medical University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
Conditions: Advanced Hepatocellular Carcinoma Interventions: Biological: ZG005 Powder for Injection; Drug: Donafenib Tosilate Tablets; Biological: Bevacizumab Sponsors: Changsha Taihe Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Conditions: Hepatocellular Carcinoma; Radiotherapy; Tislelizumab; Tumor Thrombosis Interventions: Radiation: Moderate-dose Hypofractionated Intensity-modulated Radiotherapy; Drug: Tislelizumab Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Brazilian Reality of Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma; Hepatocellular Carcinoma by BCLC Stage; Hepatocellular Carcinoma Stage I; Hepatocellular Carcinoma Stage II; Hepatocellular Carcinoma Stage III Sponsors: Hospital Israelita Albert Einstein; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
SHEPHERD(SHort-acting Embolization Particles for Patients With HEpatocellular Carcinoma Treated by RaDioembolization)
Conditions: Hepatocellular Carcinoma Interventions: Device: NexGel Sponsors: Next Biomedical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Conditions: Lung Cancer, Non-small Cell; Lung Cancer Metastatic; Solid Tumor, Adult; Advanced Cancer; Lung Cancer, Small Cell; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Sarcoma; Metastatic Osteosarcoma Interventions: Biological: KB707 Sponsors: Krystal Biotech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Liver Transplantation
Conditions: Hepatocellular Carcinoma Interventions: Radiation: Stereotactic Body Radiotherapy (SBRT) Sponsors: Assistance Publique - H ôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials
A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)
Conditions: Hepatocellular Carcinoma Interventions: Biological: Peptide-based hepatocellular carcinoma vaccine IMA970A; Combination Product: Durvalumab; Other: Montanide (Adjuvant) Sponsors: National Cancer Institute, Naples Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials
A Phase II, Single-arm, Multicenter, Prospective Study of Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
Conditions: Cadonilimab and Lenvatinib Interventions: Drug: Cadonilimab lenvatinib Sponsors: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials
Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment
Conditions: Hepatocellular Carcinoma Interventions: Drug: NP-101 Sponsors: University of Florida; Novatek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials
HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)
Conditions: Hepatocellular Carcinoma With PVTT Interventions: Drug: Tislelizumab; Drug: Lenvatinib Sponsors: Li Xiao Wei Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
Conditions: Solid Tumors; Non Small Cell Lung Cancer; Hepatocellular Carcinoma Interventions: Drug: BI-1910; Drug: Pembrolizumab Sponsors: BioInvent International AB Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.
Conditions: Carcinoma, Hepatocellular Interventions: Other: Immunotherapy, targeted therapy. Sponsors: Qianfoshan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.
Conditions: Hepatocellular Carcinoma; Narrow Margin; Radiotherapy Interventions: Radiation: Adjuvant SIB radiotherapy Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
